Searchable abstracts of presentations at key conferences in endocrinology

ea0050p045 | Bone and Calcium | SFEBES2017

Uniparental isodisomy as a cause of the autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) syndrome

Cranston Treena , Boon Hannah , Ryan Fiona , Shears Debbie , Thakker Rajesh , Hannan Fadil

The autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) syndrome is an autosomal recessive disorder characterized by immune deficiency and the autoimmune destruction of endocrine organs such as the parathyroids, adrenal cortex and ovaries. APECED is caused by biallelic germline mutations of the autoimmune regulator (AIRE) gene on chromosome 21q22.3, which is expressed in thymic medullary epithelial cells and plays a key role ...

ea0050p182 | Clinical Biochemistry | SFEBES2017

Clinical evaluation of a multiple-gene sequencing panel for hypoparathyroidism

Stokes Victoria , Cranston Treena , Boon Hannah , Gorvin Caroline , Hannan Fadil , Thakker Rajesh

Hypoparathyroidism may occur as: a hereditary syndromic disorder (e.g. Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED), Hypoparathyroidism Sensorineural Deafness and Renal Disease (HDR), Autosomal Dominant Hypoparathyroidism type 1 (ADH1), or ADH type 2 (ADH2), which are due to mutations of autoimmune regulator (AIRE), GATA binding protein 3 (GATA3), calcium-sensing receptor (CASR) and G-protein sub...

ea0050p242 | Neoplasia, Cancer and Late Effects | SFEBES2017

Combination of JQ1, an inhibitor of epigenetic pathways, and everolimus for treatment of pancreatic and bronchial neuroendocrine tumours

Lines Kate E , Stevenson Mark , Filippakopoulos Panagis , Grozinsky-Glasberg Simona , Bountra Chas , Thakker Rajesh V

Current treatments, including surgery, medical therapy, radiotherapy, and radionuclide therapy for neuroendocrine tumours of the pancreas (PNETs) and bronchus (BNETs) are often unsatisfactory, leading to a 5-year survival of <50% and 5%, respectively. PNETs and BNETs frequently have mutations in chromatin-remodelling genes and the protein encoded by the multiple endocrine neoplasia type 1 (MEN1) gene, menin. Menin binds the...

ea0086p42 | Endocrine Cancer and Late Effects | SFEBES2022

Hydroxymethylation is dysregulated in pancreatic neuroendocrine tumours and associated with aberrant DNA methylation

English Katherine A , Selberherr Andreas , Shariq Omair A , O'Neill Eric , Lines Kate W , Thakker Rajesh V

Pancreatic neuroendocrine tumours (PNETs) have a lower mutational burden than other tumours, indicating that other mechanisms contribute to tumourigenesis. One such reported mechanism is DNA methylome dysregulation, however, inconsistencies have been observed between gene methylation and protein expression, potentially stemming from the use of standard methylation assessment methods which do not distinguish methylation (5’methylcytosine (5’mC), repressive mark) from ...

ea0065oc3.4 | Bone and Calcium | SFEBES2019

Characterisation of rare GNA11 variants reveals 8 novel residues important for signalling by the calcium-sensing receptor: Relevance for FHH and ADH

Gluck Anna , Lines Kate , Gorvin Caroline , Inoue Asuka , Hannan Fadil , Breitwieser Gerda , Thakker Rajesh

The calcium-sensing receptor (CaSR) is a G-protein coupled receptor that predominantly signals via Gαq/11-mediated pathways to regulate extracellular calcium (Ca2+e) homeostasis. Germline Gα11 inactivating and activating mutations cause familial hypocalciuric hypercalcaemia type-2 (FHH2) and autosomal dominant hypocalcaemia type-2 (ADH2), respectively. To date, four FHH2 and six ADH2 mutations have been reported. To identif...

ea0065oc3.5 | Bone and Calcium | SFEBES2019

Mutational analysis of a patient with familial hypocalciuric hypercalcaemia identifies a novel p.Ser182Cys mutation, which is predicted to disrupt the calcium sensing receptor (CaSR) extracellular domain

Healy Ultan , Olesen Mie Kronborg , Jafar-Mohammadi Bahram , Hannan Fadil M , Thakker Rajesh V

Familial hypocalciuric hypercalcaemia (FHH) is an inherited disorder of calcium homeostasis, which is caused by germline loss-of-function mutations of the calcium-sensing receptor (CaSR) in ˜70% of cases. We report a 22 year old woman who was referred with asymptomatic hypercalcaemia. Biochemical investigations revealed hypercalcaemia on 3 of 4 occasions with adjusted serum calcium ranging from 2.59–2.80 mmol/l (normal range 2.20–2.60 mmol/l). Parathyroid hormon...

ea0065oc3.6 | Bone and Calcium | SFEBES2019

The role of biased calcium-sensing receptor signalling in urinary calcium excretion and kidney stone disease

Goldsworthy Michelle , Bayliss Asha , Gluck Anna , Wiberg Akira , Turney Benjamin , Furniss Dominic , Thakker Rajesh , Howles Sarah

Nephrolithiasis is a major clinical and economic health burden. We performed a genome-wide association study in British and Japanese nephrolithiasis populations and identified twenty nephrolithiasis-associated loci, five of which (DGKD, DGKH, WDR72, GPIC1 and BCR) were predicted to influence calcium-sensing receptor (CaSR) signalling. Gain-of-function CaSR-signalling pathway mutations cause enhanced signalling via intracellular calcium ([Ca2+]...

ea0065op6.3 | Neuroendocrinology, Pituitary and Neoplasia | SFEBES2019

JQ1 treatment significantly reduces POMC expression and ACTH secretion from the corticotrophinoma cell line, AtT20

Lines Kate E , Filippakopoulos Panagis , Stevenson Mark , Bountra Chas , Thakker Rajesh V

Corticotrophinomas represent >10% of all surgically removed pituitary adenomas, which are the most commonly encountered intracranial neoplasms that are identified in >25% of unselected autopsies and approximately 20% of the population undergoing intracranial imaging. Corticotrophinomas are associated with hypersecretion of adrenocorticotropic hormone (ACTH), which leads to excessive production of glucocorticoids by the adrenal cortex and the resulting hypercortisolemia causes ...

ea0065p140 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

A cyclin dependent kinase inhibitor 1B missense mutation (Pro69Leu) is associated with familial hypomagnesaemia, but not multiple endocrine neoplasia type 4 (MEN4)

Stevenson Mark , Olinger Eric , Debaix Huguette , Vogt Bruno , Devuyst Olivier , Thakker Rajesh

Mutations in cyclin dependent kinase inhibitor 1B (CDKN1B) are associated with multiple endocrine neoplasia type 4 (MEN4), in which patients typically develop parathyroid and anterior pituitary tumours, and occasionally tumours of the pancreas, adrenals, kidneys and reproductive organs. Here, we report a family with a missense mutation of CDKN1B (p.Pro69Leu) that did not have MEN4-associated tumours, but instead had hypomagnesaemia. The proband, presented wit...

ea0062oc4 | Oral Communications | EU2019

A novel PHEX mutation, p.(Trp749Ter), is associated with hypophosphataemia and rhabdomyolysis in adulthood

de Mezquita Kirsty Mills , Olesen Mie , Brown Rebecca , Sloman Melissa , Thakker Rajesh , Hannan Fadil

Case History: X-linked hypophosphataemia (XLH) manifests as rickets in infancy or childhood, and is caused by mutations of the phosphate-regulating neutral endopeptidase (PHEX) gene, which leads to excess production of the fibroblast growth factor-23 (FGF-23) hormone. We present a case illustrating that mutation of PHEX can also cause hypophosphataemia presenting in adulthood. The proband is a 56-year-old male, who was referred with persistent hypophosphataem...